Celsentri

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
22-08-2022

Ingredient activ:

maraviroc

Disponibil de la:

ViiV Healthcare B.V.

Codul ATC:

J05AX09

INN (nume internaţional):

maraviroc

Grupul Terapeutică:

Antivirals for systemic use

Zonă Terapeutică:

HIV Infections

Indicații terapeutice:

Celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable,

Rezumat produs:

Revision: 28

Statutul autorizaţiei:

Authorised

Data de autorizare:

2007-09-18

Prospect

                                92
B. PACKAGE LEAFLET
93
PACKAGE LEAFLET: INFORMATION FOR THE USER
CELSENTRI 25 MG FILM-COATED TABLETS
CELSENTRI 75 MG FILM-COATED TABLETS
CELSENTRI 150 MG FILM-COATED TABLETS
CELSENTRI 300 MG FILM-COATED TABLETS
maraviroc
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them, even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See Section 4.
WHAT IS IN THIS LEAFLET
1.
What CELSENTRI is and what it is used for
2.
What you need to know before you take CELSENTRI
3.
How to take CELSENTRI
4.
Possible side effects
5.
How to store CELSENTRI
6.
Contents of the pack and other information
1.
WHAT CELSENTRI IS AND WHAT IT IS USED FOR
CELSENTRI contains a medicine called maraviroc. Maraviroc belongs to a
group of medicines
called
_CCR5 antagonists_
. CELSENTRI works by blocking a receptor called CCR5 which HIV uses
to enter and infect your blood cells.
CELSENTRI IS USED TO TREAT HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV-1)
IN ADULTS,
ADOLESCENTS AND CHILDREN OF 2 YEARS AND OLDER, AND WEIGHING AT LEAST
10 KG.
CELSENTRI must be taken in combination with other medicines which are
also used to treat the
HIV infection. These medicines are all called
_anti-HIV medicines _
or
_ antiretrovirals_
.
CELSENTRI, as part of combination therapy, reduces the amount of virus
in your body, and keeps
it at a low level. This helps your body to increase the CD4 cell count
in your blood. CD4 cells are a
type of white blood cell that are important in helping your body to
fight infection.
2
WHAT YOU NEED TO KNOW BEFORE YOU TAKE CELSENTRI
DO NOT TAKE CELSENTRI
•
if you (or your child, if they are the patient) are
ALLERGIC
to maravir
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
CELSENTRI 25 mg film-coated tablets
CELSENTRI 75 mg film-coated tablets
CELSENTRI 150 mg film-coated tablets
CELSENTRI 300 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
CELSENTRI 25 mg film-coated tablets
Each film-coated tablet contains 25 mg of maraviroc.
Excipient with known effect: each 25 mg film-coated tablet contains
0.14 mg of soya lecithin.
CELSENTRI 75 mg film-coated tablets
Each film-coated tablet contains 75 mg of maraviroc.
Excipient with known effect: each 75 mg film-coated tablet contains
0.42 mg of soya lecithin.
CELSENTRI 150 mg film-coated tablets
Each film-coated tablet contains 150 mg of maraviroc.
Excipient with known effect: each 150 mg film-coated tablet contains
0.84 mg of soya lecithin.
CELSENTRI 300 mg film-coated tablets
Each film-coated tablet contains 300 mg of maraviroc.
Excipient with known effect: each 300 mg film-coated tablet contains
1.68 mg of soya lecithin.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
CELSENTRI 25 mg film-coated tablets
Blue, biconvex, oval film-coated tablets, approximate dimensions 4.6
mm x 8.0 mm and debossed
with “MVC 25”.
CELSENTRI 75 mg film-coated tablets
Blue, biconvex, oval film-coated tablets, approximate dimensions 6.74
mm x 12.2 mm and
debossed with “MVC 75”.
CELSENTRI 150 mg film-coated tablets
Blue, biconvex, oval film-coated tablets, approximate dimensions 8.56
mm x 15.5 mm and
debossed with “MVC 150”.
CELSENTRI 300 mg film-coated tablets
Blue, biconvex, oval film-coated tablets, approximate dimensions 10.5
mm x 19.0 mm and
debossed with “MVC 300”.
3
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
CELSENTRI, in combination with other antiretroviral medicinal
products, is indicated for
treatment-experienced adults, adolescents and children of 2 years of
age, and older
and weighing at
least 10 kg infected with only CCR5-tropic HIV-1 detectable (see
sections 4.2 and 5.1).
4.2
POSOLO
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului bulgară 22-08-2022
Raport public de evaluare Raport public de evaluare bulgară 18-07-2017
Prospect Prospect spaniolă 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului spaniolă 22-08-2022
Raport public de evaluare Raport public de evaluare spaniolă 18-07-2017
Prospect Prospect cehă 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului cehă 22-08-2022
Raport public de evaluare Raport public de evaluare cehă 18-07-2017
Prospect Prospect daneză 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului daneză 22-08-2022
Raport public de evaluare Raport public de evaluare daneză 18-07-2017
Prospect Prospect germană 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului germană 22-08-2022
Raport public de evaluare Raport public de evaluare germană 18-07-2017
Prospect Prospect estoniană 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului estoniană 22-08-2022
Raport public de evaluare Raport public de evaluare estoniană 18-07-2017
Prospect Prospect greacă 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului greacă 22-08-2022
Raport public de evaluare Raport public de evaluare greacă 18-07-2017
Prospect Prospect franceză 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului franceză 22-08-2022
Raport public de evaluare Raport public de evaluare franceză 18-07-2017
Prospect Prospect italiană 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului italiană 22-08-2022
Raport public de evaluare Raport public de evaluare italiană 18-07-2017
Prospect Prospect letonă 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului letonă 22-08-2022
Raport public de evaluare Raport public de evaluare letonă 18-07-2017
Prospect Prospect lituaniană 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului lituaniană 22-08-2022
Raport public de evaluare Raport public de evaluare lituaniană 18-07-2017
Prospect Prospect maghiară 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului maghiară 22-08-2022
Raport public de evaluare Raport public de evaluare maghiară 18-07-2017
Prospect Prospect malteză 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului malteză 22-08-2022
Raport public de evaluare Raport public de evaluare malteză 18-07-2017
Prospect Prospect olandeză 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului olandeză 22-08-2022
Raport public de evaluare Raport public de evaluare olandeză 18-07-2017
Prospect Prospect poloneză 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului poloneză 22-08-2022
Raport public de evaluare Raport public de evaluare poloneză 18-07-2017
Prospect Prospect portugheză 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului portugheză 22-08-2022
Raport public de evaluare Raport public de evaluare portugheză 18-07-2017
Prospect Prospect română 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului română 22-08-2022
Raport public de evaluare Raport public de evaluare română 18-07-2017
Prospect Prospect slovacă 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului slovacă 22-08-2022
Raport public de evaluare Raport public de evaluare slovacă 18-07-2017
Prospect Prospect slovenă 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului slovenă 22-08-2022
Raport public de evaluare Raport public de evaluare slovenă 18-07-2017
Prospect Prospect finlandeză 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului finlandeză 22-08-2022
Raport public de evaluare Raport public de evaluare finlandeză 18-07-2017
Prospect Prospect suedeză 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului suedeză 22-08-2022
Raport public de evaluare Raport public de evaluare suedeză 18-07-2017
Prospect Prospect norvegiană 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului norvegiană 22-08-2022
Prospect Prospect islandeză 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului islandeză 22-08-2022
Prospect Prospect croată 22-08-2022
Caracteristicilor produsului Caracteristicilor produsului croată 22-08-2022
Raport public de evaluare Raport public de evaluare croată 18-07-2017

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor